LLMs have made learning a lot more fun for me. It hasn't made me lazier (yet) as I might've expected. I find myself being more curious, and learning a lot more per day. This is a bit surprising to me, and awesome.
Same goes for programming. Removing all the code I generate with LLMs from consideration (which is a lot), the amount of code I write on top of that has also increased. Again, to me, this is surprising.
I think it's because I'm more energized and excited by the overall productivity boost.
Anyway, we live in exciting times!
Introducing Sora, our text-to-video model.
Sora can create videos of up to 60 seconds featuring highly detailed scenes, complex camera motion, and multiple characters with vibrant emotions.
https://t.co/YYpOAcrXQ3
Prompt: “Beautiful, snowy Tokyo city is bustling. The camera moves through the bustling city street, following several people enjoying the beautiful snowy weather and shopping at nearby stalls. Gorgeous sakura petals are flying through the wind along with snowflakes.”
Enables control of your phone or computer, and through them almost any device, just by thinking.
Initial users will be those who have lost the use of their limbs.
Imagine if Stephen Hawking could communicate faster than a speed typist or auctioneer. That is the goal.
ChatGPT can now browse the internet to provide you with current and authoritative information, complete with direct links to sources. It is no longer limited to data before September 2021.
ChatGPT can now see, hear, and speak. Rolling out over next two weeks, Plus users will be able to have voice conversations with ChatGPT (iOS & Android) and to include images in conversations (all platforms).
https://t.co/uNZjgbR5Bm
We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study!
This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people.
Recruitment is not yet open for our clinical trial. We’ll announce more information on this soon!